Panel experts voiced their support for allowing drug and health care companies to access the power of social networks during the Food and Drug Law Institute’s recent Advertising and Promotion Conference in Washington, D.C.

These experts discussed how to communicate the message of drug and health care product safety and risk to the public as they wait for the Food and Drug Administration to set guidelines online pharmacy without prescription on how health care companies and marketers can proceed into the social-media space — regulation that are expected by the end of the year.

Want to keep track of the conversation around the FDA special hearings on internet and social media?

This #FDASM aggregator site from Ignite Health should do the trick.

The site was created to capture conversations and resources related to the Nov. 12-13 FDA public hearing on how FDA-regulated product manufacturers use the Internet and social media.

A mobile version of the site is also available.

Check out some of the most recent tweets on the site:

• From @rohal: Dermatologists, Med Oncologists are the Top Phys Spec Groups Communicating with Patients Online http://bit.ly/bHvqoL #hcsmeu #pharma #hcsm

These days, it’s common for consumers to discuss drugs and treatments on health care social networks like WebMD, as well as on general social networks like Twitter.

Yet the pharmaceutical industry has thus far been unable to participate in social media — not because they are prohibited by law, but because there is a lack of clear regulatory guidelines for marketing on social networks and other web sites.

Still, in April, the FDA sent warning letters to 14 companies, claiming they violated regulations regarding presentation of fair balance in search engine ads, according to AdvertisingAge.